Vents MagaZine Music and Entertainment Magazine
Related Articles
At a panel at LSI USA ‘24, industry leaders came together to discuss the critical steps required to transition from pre-FDA clearance to successful medtech commercialization. Here are six key points that emerged from the discussion.
1. Early FDA Engagement
Early and proactive engagement with the FDA is crucial for medtech companies. Treating the FDA as a collaborative partner rather than an adversary can significantly smooth the approval process and help avoid costly delays later on.
“Even though you don’t want to treat the FDA as your friend, you need to treat them as your friend and as a consultant as much as possible,” noted Pierre Lemire, CEO of Kent Imaging. This perspective underscores the importance of building a constructive relationship with the regulatory body early in the product development process.
2. Clear Reimbursement Strategy
Establishing a clear reimbursement strategy is essential for success in the medtech market. Companies must consider both clinical claims and economic value propositions to ensure payors and providers see the device’s value.
Cody Simmons, CEO of Derma Sensor, emphasized the importance of this approach: “We invested a significant amount upfront to assess the reimbursement landscape and get that clarity upfront.” This strategic planning helps align the product with market needs and payor expectations.
3. Utilize Augmented Talent
Employing experienced professionals on a temporary basis can provide the necessary expertise without the long-term commitment—especially when transitioning from R&D to medtech commercialization.
Scott Janssen, Co-Founder of LS Associates, explained, “Use augmented consulting talent to make sure that roadmap looks good and that you have every chance of success to move forward.” This approach helps companies bring in specific skills and knowledge as needed, ensuring that all critical areas are covered without overextending resources.
4. Continuous Clinical Validation
Ongoing clinical validation is crucial for maintaining product relevance and gaining market acceptance. A strategic approach to obtaining and utilizing clinical data can facilitate both adoption and reimbursement.
“When you do graduate with your FDA approval, you need a strategy for additional clinical validation,” said Luc Marengere, Managing Partner at TVM Capital Life. This continuous effort ensures the product remains competitive and meets the market’s evolving needs.
5. Navigating Regulatory and Reimbursement Pathways
While FDA approval is a significant milestone, securing reimbursement is equally important and requires a separate, though interlinked, strategy. Companies must effectively navigate both pathways to ensure comprehensive market success.
Pierre Lemire highlighted this challenge: “The FDA path is easy compared to reimbursement. If CMS doesn’t provide guidance on payment for that code, they’ll say it’s up to the MACs. So, now, you’re battling with each MAC who has the authority to set their own policies on that code.” Understanding and preparing for these complexities early can make a substantial difference in market entry and growth.
6. Robust Manufacturing and Supply Chain Management
Ensuring robust manufacturing processes and reliable supply chains is critical for scaling up production and meeting market demand. Companies must plan for scalability and avoid rushing to market without adequate preparation.
Luc Marengere warned, “When you start manufacturing, you need to have a quality mindset. You need to have a quality engineer who reports to the CEO, not the guy who runs R&D.” Proper planning and execution in manufacturing and supply chain management can prevent costly mistakes and ensure consistent product availability.
Conclusion
The full recording of the panel can be found in LSI’s resource hub at the link below:
The market requires a strategic and well-orchestrated approach to transition from pre-FDA approval to full-scale medtech commercialization. Insights shared during the panel discussion highlighted the importance of early FDA engagement, a clear reimbursement strategy, utilizing augmented talent, continuous clinical validation, navigating regulatory and reimbursement pathways, and robust manufacturing and supply chain management.
Understanding these critical steps can significantly influence decision-making and drive successful market entry and growth. By incorporating these strategies, medtech companies can better position themselves for success in an increasingly competitive market.
